Also known as: Phase IV trial, Postmarketing study, Post-approval study
Key facts
- Timing
- After FDA approval, while the product is on the market
- Authority to require safety studies
- FD&C Act Section 505(o)(3), added by FDAAA in 2007
- FDA categories
- Postmarketing requirements (PMRs) and commitments (PMCs)
- Other required studies
- Accelerated approval confirmatory trials, deferred PREA pediatric studies
What is a Phase 4 clinical trial?
Phase 4 covers studies done after a product is approved. Premarket trials are limited in size, duration and population, so rare side effects, long-term outcomes and effects in groups that were underrepresented in earlier trials often become clear only after wider use.
The term is used loosely. It can mean a randomized trial required by FDA, a large safety study, an observational registry, or a study a company runs to compare its product with alternatives in routine practice. Only the interventional studies among these are clinical trials in the strict sense.
Types of Phase 4 studies
Post-approval studies fall into a few groups:
- Postmarketing requirements (PMRs): studies FDA can require, for example under FD&C Act Section 505(o)(3) to assess a known or potential serious risk.
- Accelerated approval confirmatory trials: studies that verify clinical benefit when approval was based on a surrogate or intermediate clinical endpoint.
- Pediatric studies required under the Pediatric Research Equity Act (PREA) that FDA deferred until after approval.
- Postmarketing commitments (PMCs): studies a sponsor agrees to conduct that are not required by statute or regulation.
- Sponsor-initiated or investigator-initiated studies: head-to-head comparisons, new populations or effectiveness in routine care.
Why Phase 4 trials matter
Phase 4 studies can change a product's label, add safety warnings or, for accelerated approvals, lead to withdrawal of an indication if clinical benefit is not confirmed. Pricing and market access analysts watch confirmatory trials closely because a failed study can remove a revenue stream.
FDA publishes the status of PMRs and PMCs, and many Phase 4 trials are registered on ClinicalTrials.gov, so analysts can check whether a sponsor is meeting its post-approval obligations. Medical affairs teams also use Phase 4 results in formulary discussions and scientific exchange with clinicians.